Soluble CD14 Subtype—A New Biomarker in Predicting the Outcome of Critically Ill Septic Patients

Matera, Giovanni; Quirino, Angela; Peronace, Cinzia; Settembre, Pio; Marano, Vito; Loria, Maria Teresa; Marascio, Nadia; Galati, Luisa; Barreca, Giorgio Settimo; Giancotti, A; Amantea, B; Liberto, Maria Carla; Focà, Alfredo

doi:10.1016/j.amjms.2017.03.036

Cited by 22 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean age of the populations varied between 55.2 and 71.5 years, and the proportion of men ranged from 30.3% to 72.4%. Five studies were performed in the ICU,22,33,35,36,39 three in the ED37,38,40 and one in both the ICU and ED 34. There are six prospective studies,22,35–39 two were designed as retrospective recruitments33,34 and one is unknown 25.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies were performed in the ICU,22,33,35,36,39 three in the ED37,38,40 and one in both the ICU and ED 34. There are six prospective studies,22,35–39 two were designed as retrospective recruitments33,34 and one is unknown 25. Of these, diagnosis as sepsis was defined as “gold standard” by the criteria in 1991 ACCP/SCCM consensus conference (1992 criteria) in four studies,22,25,38,39 by 2001 ACCP/SCCM consensus conference in two,35,37 by the third international consensus definitions for sepsis and septic shock (sepsis-3) in two34,36 and one was carried out according to the Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 33.…”

Section: Resultsmentioning

confidence: 99%

“…There are six prospective studies,22,35–39 two were designed as retrospective recruitments33,34 and one is unknown 25. Of these, diagnosis as sepsis was defined as “gold standard” by the criteria in 1991 ACCP/SCCM consensus conference (1992 criteria) in four studies,22,25,38,39 by 2001 ACCP/SCCM consensus conference in two,35,37 by the third international consensus definitions for sepsis and septic shock (sepsis-3) in two34,36 and one was carried out according to the Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 33. Levels of the circulating presepsin were measured by a chemiluminescent immunoassay on a PATHFAST immunoanalyzer in all studies (Mitsubishi Chemical or LSI Medience Corporation, Tokyo, Japan or Mitsubishi Chemical Europe GmbH, Dusseldorf, Germany).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

<p>The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis</p>

Zhu¹,

Li²,

Guo³

et al. 2019

TCRM

View full text Add to dashboard Cite

Objective: The soluble cluster of differentiation 14 subtype (sCD14-ST) or presepsin has recently been identified as a promising biomarker in sepsis. The present meta-analysis is performed to assess the prognostic value of presepsin in septic patients. Further, we compare the prognostic performance between presepsin and procalcitonin (PCT) in predicting all-cause mortality in these patients. Methods: A systemic and comprehensive search was conducted in PubMed, Embase and Cochrane databases by using Exploded Medical Subject Headings and appropriate corresponding keywords. Studies were eligible if they assessed the prognostic value of presepsin in sepsis and provided sufficient information to construct a 2×2 contingency table. A bivariate meta-analysis model was used to calculate the pooled sensitivity, specificity, positive/negative likelihood ratios and diagnostic odds ratio. The Chi-square and I 2 index were used to assess the heterogeneity and inconsistency. The Deek’s funnel plot asymmetry test was used to assess the likelihood of publication bias. Results: Nine publications, comprising 1,561 patients, were included in this study. The overall area under the receiver operating characteristic curve (AUROC) of presepsin was 0.77 (95% CI, 0.73–0.81) with a pooled prognostic sensitivity (SEN) and specificity (SPE) of 0.83 (95% CI, 0.72–0.90) and 0.69 (95% CI, 0.63–0.74), respectively. Additionally, the PLR, NLR and DOR of presepsin were 2.6 (95% CI, 2.1–3.3), 0.25 (95% CI, 0.15–0.44) and 10 (95% CI, 5–22), respectively. The AUROC of PCT was 0.81 (95% CI, 0.78–0.84) with a pooled SEN of 0.76 (95% CI, 0.55–0.89) and SPE of 0.74 (95% CI, 0.33–0.94). There is no statistically significant difference in the performance of pooled SEN and SPE between presepsin and PCT, with a p value of 0.39 and 0.71, respectively. Conclusions: Based on the results of this meta-analysis, both presepsin and PCT are promising biomarkers for the prognosis of mortality in sepsis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

<p>The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis</p>

Zhu¹,

Li²,

Guo³

et al. 2019

TCRM

View full text Add to dashboard Cite

show abstract

“…Matera et al [39] in an observational, prospective study assessed 58 surgical and medical ICU patients with suspected sepsis. Taking into consideration the 28-day mortality and blood culture results the study group was retrospectively divided into survivor and non-survivor subgroups, and positive and negative microbiological result subgroups.…”

Section: Role Of Presepsin In Sepsismentioning

confidence: 99%

“…Results of multivariate analysis indicated that presepsin is an independent predictive variable among prognosis markers at T-0 (P = 0.016). Based on these results, the authors assessed presepsin as an interesting prognostic and diagnostic biomarker in patients with severe sepsis [39].…”

Section: Role Of Presepsin In Sepsismentioning

confidence: 99%

Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

Mierzchała-Pasierb¹,

Lipińska-Gediga²

2019

ait

View full text Add to dashboard Cite

Sepsis is a life-threatening organ dysfunction caused by a systemic altered host response to infection. According to the newest guidelines the sepsis treatment should be personalized and based on an approach specified by use of biomarkers to tailor therapy to each patient's needs. The main features of such biomarkers should be high specificity, sensitivity and ability to monitor the progress of sepsis. There is limited application of procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) for reaching this target, because of their secretion during non-infectious processes. The purpose of this review was to introduce four biomarkers, i.e. kallistatin, testican-1, presepsin and mid-regional pro-adrenomedullin, and compare their usefulness in diagnosing sepsis with PCT, CRP and IL-6.

show abstract

Sepsis Biomarkers

Vincent¹,

Lelubre²

2018

Handbook of Sepsis

View full text Add to dashboard Cite

Soluble CD14 Subtype—A New Biomarker in Predicting the Outcome of Critically Ill Septic Patients

Cited by 22 publications

References 35 publications

<p>The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis</p>

<p>The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis</p>

Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?

Sepsis Biomarkers

Contact Info

Product

Resources

About